Please assess the completion status of the following clinical trial:

Trial Title: A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed informed consent/ paediatric assent (if applicable) prior to any study specific procedures including medication withdrawal~* Male or Female, ≥12 years of age~* Documented clinical diagnosis of asthma for at least 1 year prior to Visit 2~* Patient must have history of at least 1 asthma exacerbation including one of the following:~  * requiring treatment with systemic corticosteroids~ * an asthma-related hospitalization between 4 weeks and 12 months prior to randomization~* Current Asthma Therapy: Patients must be appropriately using one of the treatments for asthma listed in the protocol combined with achieving certain results when recording an Asthma Control Questionnaire~Exclusion Criteria:~* Patient has a history of life-threatening asthma. Defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea requiring non-invasive ventilatory support.~* Patient has required treatment with systemic corticosteroids (tablets, suspensions or injectable) for any reason within 4 weeks prior to Visit 2~* Patient has an ongoing exacerbation, defined as a worsening of asthma that requires treatment with systemic corticosteroids (tablets, suspension, or injectable)~* An asthma exacerbation within 4 weeks of randomization or more than 4 separate exacerbations in the 12 months preceding randomization or more than 2 hospitalizations for treatment of asthma in the 12 months preceding randomization~* Patient has a respiratory infection or other viral/bacterial illness, or is recovering from such an illness at the time of Visit 2 that, in the investigator's opinion, will interfere with the patient's lung function~* Patient must not meet unstable asthma severity criteria as listed in the protocol~* Peak expiratory flow must not be below 50% o predicted normal~* Pregnancy, breast-feeding or planned pregnancy during the study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Symbicort
- 2 (Type: ACTIVE_COMPARATOR): budesonide

Based on this trial design, predict the completion outcome and termination type (if applicable).